


9/29/04

L3 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB Title compds. [I; X is N or CH; Y is NR₂CH₂, CH₂NR₂, NR₂CO, CONR₂, NR₂SO₂; R₂ is H or C₁-C₆ alkyl; R₁ is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl; R₃ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, (CH₂)_n-aryl; aryl is Ph or a heteroarom. ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; R₉ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OCF₃, OCHF₂, OCH₂F, halogen, CONR₆R₇, CN, CF₃, OH, C₁-C₆ alkoxy, NR₆R₇, SO₃CH₃, SO₃CF₃, SO₂NR₆R₇, an unsubstituted or substituted heterocyclic or heteroarom. ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C₁-C₆ alkyl, COR₈; R₆, R₇ and R₈ are as defined above], as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof are prepared via acylation and alkylation; pharmaceutical compns. containing said therapeutically active compds. and to the use of said active compds. in therapy are included. (S)-N-[8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-(dimethylaminocarbonyl)benzamide was prepared

AN 1999:216915 CAPLUS

DN 130:223067

TI Preparation of substituted chroman derivatives

IN Berg, Stefan; Linderberg, Mats; Ross, Svante; Thorberg, Seth-Olov; Ulff, Bengt

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914213	A1	19990325	WO 1998-SE1604	19980909
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


~~10725187~~

10/714577

9/29/04

ZA 9807806	A	19990318	ZA 1998-7806	19980827
CA 2303926	AA	19990325	CA 1998-2303926	19980909
AU 9891933	A1	19990405	AU 1998-91933	19980909
BR 9812239	A	20000718	BR 1998-12239	19980909
EP 1025096	A1	20000809	EP 1998-944378	19980909
EP 1025096	B1	20031126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000737	T2	20000921	TR 2000-200000737	19980909
EE 200000144	A	20010215	EE 2000-200000144	19980909
JP 2001516755	T2	20011002	JP 2000-511762	19980909
AT 255099	E	20031215	AT 1998-944378	19980909
US 6387899	B1	20020514	US 1998-171572	19981021
HR 2000000133	A1	20011231	HR 2000-133	20000309
NO 2000001403	A	20000518	NO 2000-1403	20000317
US 6384225	B1	20020507	US 2000-653552	20000831
PRAI SE 1997-3378	A	19970918		
WO 1998-SE1604	W	19980909		
US 1998-171572	A3	19981021		
OS MARPAT 130:223067				
IT 221185-10-0P 221185-13-3P 221185-19-9P 221185-24-6P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of substituted chroman derivs.)				
RN 221185-10-0	CAPLUS			
CN	2H-1-Benzopyran-8-carboxylic acid, 3-[bis(phenylmethyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, methyl ester, (3S)- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.




RN 221185-13-3 CAPLUS
CN 2H-1-Benzopyran-8-methanol, 3-[bis(phenylmethyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10725181

214 577


9/29/04



RN 221185-19-9 CAPLUS

CN 2H-1-Benzopyran-8-carboxamide, 3-[bis(phenylmethyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221185-24-6 CAPLUS


CN 2H-1-Benzopyran-8-carboxamide, 3-[(4-benzoylbenzoyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10725181

10/714577

9/29/04



IT 221185-17-7P 221185-27-9P 221185-41-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of substituted chroman derivs.)

RN 221185-17-7 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221185-27-9 CAPLUS


CN 1,4-Benzenedicarboxamide, N'-[(3S)-3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

~~10725181~~


10/714577

9/29/04



RN 221185-41-7 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, 3,4-dihydro-8-methoxy-5-(4-methyl-1-piperazinyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



IT 221185-02-0P 221185-05-3P 221185-08-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted chroman derivs.)

RN 221185-02-0 CAPLUS


CN 2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

10725181

714577


9/29/04



RN 221185-05-3 CAPLUS

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 221185-08-6 CAPLUS

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-8-iodo-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



~~10725181~~

10/7/14 577

9/29/04

RE.CNT 4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~10725181~~

10/7/4577

9/29/04

L3 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB Piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivs. I [X = N, CH; Y = NR2CH2, CH2NR2, NR2CO, CONR2, NR2SO2, NR2CONR2 wherein R2 = H, C1-C6 alkyl; R1 = H, C1-C6 alkyl, C3-C6 cycloalkyl; R3 = C1-C6 alkyl, C3-C6 cycloalkyl, (CH2)n-aryl, wherein aryl is Ph or a heteroarom. ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n = 0-4], possessing selective effects at the h5-HT1B receptor, were prepared E.g., reaction of (S)-N-[5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-(piperazin-1-yl)benzamide with 2-benzyloxyethyl mesylate in presence of K2CO3 gave (S)-N-[5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-[4-(2-benzyloxyethyl)piperazin-1-yl]benzamide.

AN 1999:216914 CAPLUS

DN 130:237475

TI Preparation of substituted chroman derivatives and their effects at the h5-HT1B receptor

IN Berg, Stefan; Nylof, Martin; Ross, Svante; Thorberg, Seth-Olov

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914212	A1	19990325	WO 1998-SE1603	19980909
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	ZA 9807813	A	19990318	ZA 1998-7813	19980827
	CA 2304037	AA	19990325	CA 1998-2304037	19980909
	AU 9891932	A1	19990405	AU 1998-91932	19980909
	AU 734580	B2	20010614		
	BR 9812238	A	20000718	BR 1998-12238	19980909
	TR 200000736	T2	20000721	TR 2000-200000736	19980909
	EP 1025095	A1	20000809	EP 1998-944377	19980909
	EP 1025095	B1	20031126		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	EE 200000140	A	20010215	EE 2000-200000140	19980909
	JP 2001516754	T2	20011002	JP 2000-511761	19980909


10725181

10/714577

9/29/04

AT 255098	E	20031215	AT 1998-944377	19980909
US 6479497	B1	20021112	US 1998-171570	19981021
HR 2000000132	A1	20011231	HR 2000-132	20000309
NO 2000001402	A	20000509	NO 2000-1402	20000317
US 2003100556	A1	20030529	US 2002-285743	20021101
US 6670359	B2	20031230		
US 2004157857	A1	20040812	US 2003-714577	20031113
PRAI SE 1997-3377	A	19970918		
WO 1998-SE1603	W	19980909		
US 1998-171570	A3	19981021		
US 2002-285743	A3	20021101		
OS MARPAT 130:237475				
IT 221185-02-0P 221185-05-3P 221360-19-6P				
221360-92-5P 221360-93-6P 221360-97-0P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
(preparation of substituted chroman derivs. and their effects at the h5-HT1B receptor)				
RN 221185-02-0	CAPLUS			
CN	2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)			

Absolute stereochemistry. Rotation (+).




RN 221185-05-3 CAPLUS
CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

~~10725181~~

10/714577


9/29/04



RN 221360-19-6 CAPLUS

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-92-5 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221360-93-6 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-


~~10725181~~

10/714577

9/29/04

3-yl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-97-0 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-[4-[2-(phenylmethoxy)ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 221360-41-4P 221360-44-7P 221360-47-0P
221360-52-7P 221360-56-1P 221360-59-4P
221360-61-8P 221360-64-1P 221360-67-4P
221360-70-9P 221360-74-3P 221360-80-1P
221360-82-3P 221360-83-4P 221360-84-5P
221360-85-6P 221360-87-8P 221360-88-9P
221360-91-4P 221360-94-7P 221360-95-8P
221360-96-9P 221360-98-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted chroman derivs. and their effects at the h5-HT1B receptor)

RN 221360-41-4 CAPLUS


CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

~~10725181~~

10/714577


9/29/04



RN 221360-44-7 CAPLUS

CN Benzamide, N-[(3R)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 221360-47-0 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221360-52-7 CAPLUS

CN Benzamide, 4-butoxy-N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-


~~10725181~~

10/714577

9/29/04

benzopyran-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-56-1 CAPLUS

CN Benzamide, 4-butoxy-N-[(3R)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 221360-59-4 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



~~10725181~~


10/7#4577

9/29/04

RN 221360-61-8 CAPLUS

CN Benzamide, N-[(3R)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 221360-64-1 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-2,4-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221360-67-4 CAPLUS


CN Benzamide, 4-(diethylamino)-N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

~~10725181~~

10/714577


9/29/04



RN 221360-70-9 CAPLUS

CN Benzamide, 4-(diethylamino)-N-[(3R)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 221360-74-3 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221360-80-1 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-


~~10725181~~

10/7/4577

9/29/04

3-yl]-2,4-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-82-3 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-2-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-83-4 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



~~10725101~~


10714577

9/29/04

RN 221360-84-5 CAPLUS

CN Benamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-85-6 CAPLUS

CN Benzenesulfonamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 221360-87-8 CAPLUS


CN Benamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

~~10725181~~

10/714577


9/29/04



RN 221360-88-9 CAPLUS

CN Urea, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-N'-(4-(4-morpholinyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221360-91-4 CAPLUS


CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-2-methoxy-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

~~10725181~~

60/714577


9/29/04



RN 221360-94-7 CAPLUS

CN Benzamide, 4-(4-acetyl-1-piperazinyl)-N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-95-8 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 221360-96-9 CAPLUS

CN 1,4-Benzenedicarboxamide, N'-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-


~~10725181~~

10/7/4 577

9/29/04

2H-1-benzopyran-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-98-1 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-[4-(2-hydroxyethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~10725181~~

10/714577

9/29/04

L3 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB The invention relates to a combination of a first component (a) which is a 5-HT reuptake inhibitor (SSRI), and a second component (b) which is a selective h5-HT1B antagonist or partial agonist I [wherein X = CH₂ or O; Y = CONH or NHCO; R₁ = H, C₁-6 alkyl, or C₃-6 cycloalkyl; R₂ = H, C₁-6 alkyl, C₁-6 alkoxy, or halo; R₃ = morpholino, morpholinocarbonyl, 4-oxopiperidino, CF₃, or CONR₄R₅; R₄, R₅ = H or C₁-4 alkyl], as a racemate or either enantiomer, with said components (a) and (b) being in the form of free bases, solvates, or pharmaceutically acceptable salts. The invention also relates to their preparation, combination pharmaceutical formulations, use, a method of treating affective disorders such as depression, anxiety, and OCD using the combinations, as well as a kit containing the combinations. The combinations of the invention may afford a new route to faster onset of action in antidepressant therapy, and may improve the efficacy of SSRIs. For instance, amidation of 4-morpholinobenzoic acid with (R)-2-amino-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene using 1,1'-carbonyldiimidazole in DMF gave 73% II. Using II as the h5-HT1B antagonist, and citalopram as the 5-HT reuptake inhibitor, a 400% maximum increase in extracellular 5-HT was observed in the prefrontal cortex of guinea pigs, whereas citalopram alone gave a maximum increase of less than 250%.

AN 1999:219986 CAPLUS

DN 130:252382

TI A combination of a 5-HT reuptake inhibitor and a h5-HT1B antagonist or partial agonist [piperazinonaphthalene or -benzopyran derivative] for antidepressant therapy

IN Berg, Stefan; Ross, Svante; Thorberg, Seth-Olov

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

10725181—

10/714 577

9/29/04

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9913877	A1	19990325	WO 1998-SE1601	19980909
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807817	A	19990318	ZA 1998-7817	19980827
	CA 2302382	AA	19990325	CA 1998-2302382	19980909
	AU 9891930	A1	19990405	AU 1998-91930	19980909
	AU 752722	B2	20020926		
	EP 1014985	A1	20000705	EP 1998-944375	19980909
	EP 1014985	B1	20030521		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000727	T2	20000921	TR 2000-200000727	19980909
	BR 9812088	A	20000926	BR 1998-12088	19980909
	EE 200000141	A	20010215	EE 2000-200000141	19980909
	EE 4141	B1	20031015		
	JP 2001516718	T2	20011002	JP 2000-511499	19980909
	NZ 503171	A	20020201	NZ 1998-503171	19980909
	AT 240733	E	20030615	AT 1998-944375	19980909
	RU 2214824	C2	20031027	RU 2000-109563	19980909
	PT 1014985	T	20031031	PT 1998-944375	19980909
	ES 2200370	T3	20040301	ES 1998-944375	19980909
	US 6159971	A	20001212	US 1998-171580	19981021
	NO 2000001399	A	20000510	NO 2000-1399	20000317
	HK 1032739	A1	20031031	HK 2000-107438	20001121
PRAI	SE 1997-3375	A	19970918		
	WO 1998-SE1601	W	19980909		
OS	MARPAT 130:252382				
IT	221472-06-6P				
	RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)				
	(byproduct; preparation and/or therapeutic combination of 5-HT reuptake inhibitors with selective h5-HT1B antagonists or partial agonists)				
RN	221472-06-6 CAPLUS				
CN	2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

~~10725101-~~

10/714 5 77

9/29/04




IT 221185-27-9P 221185-41-7P 221360-41-4P
221360-84-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(h5-HT1B antagonist; preparation and/or therapeutic combination of 5-HT reuptake inhibitors with selective h5-HT1B antagonists or partial agonists)

RN 221185-27-9 CAPLUS

CN 1,4-Benzenedicarboxamide, N'-[(3S)-3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 221185-41-7 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, 3,4-dihydro-8-methoxy-5-(4-methyl-1-piperazinyl)-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)

~~10725181~~

10/714527


9/29/04



RN 221360-41-4 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221360-84-5 CAPLUS

CN Benzamide, N-[(3S)-3,4-dihydro-5-(4-methyl-1-piperazinyl)-2H-1-benzopyran-3-yl]-4-(4-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 221185-02-0P 221185-05-3P, (S)-3-(N,N-Dibenzylamino)-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran 221185-08-6P

~~10725181~~

10/714577

9/29/04

221185-10-0P 221185-13-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation and/or therapeutic combination of 5-HT reuptake
inhibitors with selective h5-HT1B antagonists or partial agonists)

RN 221185-02-0 CAPLUS

CN 2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-
benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 221185-05-3 CAPLUS

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-(4-methyl-1-piperazinyl)-N,N-
bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 221185-08-6 CAPLUS

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-8-iodo-5-(4-methyl-1-piperazinyl)-N,N-
bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


9/29/04



RN 221185-10-0 CAPLUS

CN 2H-1-Benzopyran-8-carboxylic acid, 3-[bis(phenylmethyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221185-13-3 CAPLUS


CN 2H-1-Benzopyran-8-methanol, 3-[bis(phenylmethyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

~~10725181~~

10/714577

9/29/04



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~10725181~~

10/714 577